Speaker Profile
Ph.D., Chief Executive Officer, Novasenta
Biography
Dr. Mohindru has served as Novasentas Chief Executive Officer and Director since April 2021. Dr. Mohindru also serves as a Board member for two public companies (CytomX Therapeutics and Cardiff Oncology). Her prior Csuite experience includes being the CEO of CereXis, Inc., CFO and Chief Strategy Officer of Cara Therapeutics, and Chief Strategy Officer of Curis. Dr. Mohindru has also spent several years on Wall St. covering the biotech sector at UBS, Credit Suisse and ThinkEquity. On the nonprofit side, she is a member of the Executive Advisory Board of the Chemistry of Life Processes Institute of Northwestern University and a member of the Scientific Investment Advisory Committee of the Gates Center of Regenerative Medicine at the University of Colorado.
Emerging Therapeutics Showcase:
Novasenta
Novasenta discovers novel immuno-oncology therapeutic targets to develop innovative and effective treatments with the goal of transforming the lives of patients with cancer.
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2024 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.
- Emerging Therapeutics/Cell Therapy
- Emerging Therapeutics/CVD
- Emerging Therapeutics/Gene Therapy
- Emerging Therapeutics/Immunotherapy
- Emerging Therapeutics/Radiation Therapy
